Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-ß and uses thereof.

Abstract: Provided are novel anti-TNFSF9 antibodies and antibody drug conjugates, and methods of using such anti-TNFSF9 antibodies and antibody drug conjugates to treat cancer.

Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The present application relates to compositions of humanized and deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to anti-endoglin antibodies which inhibit or treat fibrosis.

Abstract: The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.

Abstract: The invention provides buffered aqueous formulations of bevacizumab. The formulations comprise a citrate phosphate buffer comprising trehalose or sucrose, and polysorbate 20. The formulations have an acidic pH of from about 5.8 to about 6.0, and enhance the conformational and colloidal stability of the bevacizumab molecule. Levels of potency-reducing reversible aggregates and covalent dimers in the citrate phosphate buffer were low, and this buffer further offered protection against storage stress, but did not modify or alter any key biophysical descriptor of the antibody.

Abstract: The present invention relates to anti-GPC3 antibodies and their applications. The invention investigates the potential inhibitory effect of anti-GPC3 antibodies on tumor growth, proliferation, migration and their applications for diagnostic and therapeutic purposes.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Abstract: An embodiment of the invention relates to the use of stabilized cancer peptide fragments derived from Protocadherin FAT1 for the diagnosis of cancers, particularly pancreatic cancer. A method for the detection of cancer, severity of cancer, and/or effectiveness of a therapeutic regimen includes detecting and/or measuring the amount of Protocadherin FAT1 peptide fragments present in the biological sample of a subject.

Abstract: Provided are self-crosslinking meditope-enabled antibodies. Also provided are methods for altering the distribution of a cell surface antigen using self-crosslinking meditope enabled antibodies, compositions for use in the methods, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.

Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

Abstract: The invention provides anti-HtrA1 antibodies and methods of using the same.

Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.

Abstract: Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein i) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations H310A, H433A and Y436A, or ii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251D, L314D and L432D, or iii) the first polypeptide comprises the mutations I253A, H310A and H435A and the second polypeptide comprises the mutations L251S, L314S and L432S.

Abstract: The present disclosure relates to a dewatering systems, and related methods, that are adapted to convey lignocellulosic biomass to separate at least a portion of the water from a lignocellulosic biomass slurry and accumulate the dewatered lignocellulosic biomass. The dewatering system also includes a headspace occupied by a gas that is at a pressure that facilitates transferring the accumulated biomas into a pretreatment reactor having a pressurized headspace. Such a dewatering system can prevent undue mixing and backflow of gas (e.g., steam) from the pretreatment reactor.

Abstract: A method for at least partial deacetylation of a biopolymer comprising acetyl groups, including: a1) providing a biopolymer including acetyl groups; a2) reacting the biopolymer including acetyl groups with hydroxylamine (NH2OH) or a salt thereof at a temperature of 100° C. or less for 2-200 hours to form an at least partially deacetylated biopolymer; and a3) recovering the at least partially deacetylated biopolymer.

Abstract: The invention relates to a process for the production of polyethylene by gas phase polymerisation of ethylene in the presence of a supported chromium oxide based catalyst which is modified with an amino alcohol wherein the molar ratio of amino alcohol:chromium ranges between 0.5:1 and 1.5:1 wherein the support is silica having a surface area (SA) between 250 m2/g and 400 m2/g and a pore volume (PV) between 1.1 cm3/g and less than 2.0 cm3/g.

Abstract: This invention relates to a non-phthalate catalyst system for olefin polymerization. The non-phthalate catalyst system comprises (a) a solid Ziegler-Natta catalyst composition comprising a transition metal, a Group 2 metal, and one or more halogens; and one or more internal electron donor compounds; and (b) one or more external electron donor compounds.

Abstract: A method of producing a silane cross-linked polyethylene is disclosed which includes maleating a polyethylene polymer to form a maleated polyethylene and reacting the maleated polyethylene with a primary or secondary amino silane to form a silane-grafted polyethylene. The method further includes treating the silane-grafted polyethylene in a moisture curing process to form the silane cross-linked polyethylene.

Abstract: Catalyst composition comprising a phthalate-free electron donor, which is highly effective during polymerisation in the presence of a polymeric nucleating agent, and its use and a process for its preparation.

Abstract: Polymerization process control methods for making polyethylene are provided. The process control methods include performing a polymerization reaction in a polymerization reactor to produce the polyethylene, where ethylene, and optionally one or more comonomers, in the polymerization reaction is catalyzed by an electron donor-free Ziegler-Natta catalyst and an alkyl aluminum co-catalyst. A melt flow ratio (I21/I2) of the polyethylene removed from the polymerization reactor is measured and an amount of long chain branching (LCB) of the polyethylene from the polymerization reactor is controlled by adjusting a weight concentration of the alkyl aluminum co-catalyst present in the polymerization reactor.

Abstract: Provided herein are copolymers that comprise copolymerized residues of a perfluorotrivinyltriazine monomer of Formula 1. Preferred Rf groups include, without limitation, —(CF2)n— (n=1-6); —(CF2)m—[OCF(CF3)CF2]p— (m=1-4, p=1-4); and —[(CF(CF3)—O)x—(CF2)k]— (x=1-3, k=1-5). Preferred comonomers for copolymerization with the perfluorotrivinyltriazine monomer (1) include, without limitation, tetrafluoroethylene (TFE); vinylidene fluoride (VF2); hexafluoropropylene (HFP); vinyl fluoride (VF); EVE; PSEPVE; perfluoro-(long chain vinyl ethers); E; P; PFBE; PEVE; EVE-OH; EVE-P; PDD; and the cure-site monomers BTFB, ITFB, 8-CNVE, 8-SAVE, and the like. Also provided are methods of synthesizing the copolymers and articles comprising the copolymers.

Abstract: The present disclosure relates to rheology-modifying agents and methods of modifying the rheology of slurries. A rheology-modifying agent may be added to a slurry. The rheology-modifying agent may include a polymer and the polymer may include at least three chemically different monomers. The slurry may include lime and/or magnesium hydroxide.

Abstract: Provided is a method for preparing an acrylic copolymer, and more specifically, provided are a method for preparing an acrylic copolymer including: i) adding and polymerizing 50 to 80 parts by weight of a methyl (meth)acrylate monomer and 10 to 49 parts by weight of a C2-C12 alkyl (meth) acrylate monomer, based on 100 parts by weight of a total monomer content, in a reactor (S1); and ii) adding and polymerizing 1 to 10 parts by weight of the methyl (meth) acrylate monomer, more than 0.01 part by weight to less than 1 part by weight of an acrylic cross-linking agent, and a surfactant, based on 100 parts by weight of the total monomer content, in which a polymerization conversion ratio of the polymerization in step (S1) is 70% to 90% (S2), an acrylic copolymer prepared therefrom, and a resin composition including the same.

Abstract: (Meth)acrylate polymers are provided which have a narrow molecular weight distribution on a higher molecular weight side and can impart high shear viscosity stability to lubricating oils. A (meth)acrylate polymer (A) includes specific structural units and is such that in a differential molecular weight distribution curve obtained by gel permeation chromatography (GPC) measurement which shows the polystyrene-equivalent molecular weight of the (meth)acrylate polymer (A) normalized so that the intensity of the peak-top polystyrene-equivalent molecular weight M (t) is 1, the value a represented by a=Log Mh (t1/2)?Log M (t) is not more than 0.12 wherein Mh (t1/2) is the polystyrene-equivalent molecular weight at a point on a higher molecular weight side where the intensity is 0.5.

Abstract: To provide a liquid repellent composition whereby a treated article excellent in liquid repellency is obtainable, which is excellent in stability and does not have such a problem as an odor attributable to ammonia or an organic amine; a method for its production; and a method for producing oil resistant paper.

Abstract: The present invention relates to a method of preparing an ABS-based resin composition and a method of manufacturing an ABS-based injection-molded article including the same. More particularly, the present invention provides a method of preparing an ABS-based resin composition using a multimeric acid of unsaturated fatty acid or a metal salt thereof, as an emulsifier, in a diene-based rubber latex polymerization step and an ABS-based graft polymerization step. In accordance with the present invention, when an ABS-based resin composition is prepared using a multimeric acid of unsaturated fatty acid or a metal salt thereof as an emulsifier, stability of polymerization is secured and surface characteristics, such as surface gloss or sharpness, of an ABS-based injection-molded article are improved.

Abstract: A hydrogenated copolymer comprising a copolymer block A comprising a vinyl aromatic compound monomer unit and a conjugated diene monomer unit, wherein a tan ? peak obtained by dynamic viscoelasticity measurement (1 Hz) is in the range of ?40° C. to 20° C., a value of the tan ? peak is 0.8 or more, and a half value width of the tan ? peak is 22° C. or less.

Abstract: The present invention discloses a phosphorylated polycondensate high-performance water-reducing agent with a phosphorylated melamine derivative, instead of a conventional carboxyl group or sulfonic group, as a main adsorption group. The use of aryl alkoxypolyether as a side chain of the polymer provides a strong steric effect to improve the dispersibility and dispersion-retaining properties of the polymer. A polycondensate high-performance water-reducing agent and a method for preparing the same provided by the present invention have excellent overall performance, high adaptability for current low-grade raw materials of concrete, strong market demands, and vast application prospects. Additionally, the polycondensate has an advanced preparation process provided with the characteristics of industrially scalable production, which offers the prospect of a core technology in the field of water-reducing agent of concrete so as to promote development of the industry.

Abstract: Additives for making polyurethanes are disclosed. The additives are based on combining specific carboxylic acids or carboxylic di-acids together with a gelling catalysts obtained when mixing an isocyanate-reactive tertiary amine catalysts with dimethyl tin di carboxylate salts and/or dimethyltin mercaptide salts.

Abstract: A method forming a surface modifying composition with reduced need for organic solvent and evaporation thereof for removal of insoluble reaction byproducts from the composition. The purified composition can be used in the formation of articles having improved biocompatibility, such as medical articles (e.g., spun hollow fiber).

Abstract: A polymerizable composition comprising a) at feast one cyclic amide, b) from 2.8 to 3.5% by weight, preferably from 2.9 to 3.1% by weight, of at least one blocked polyisocyanate, and c) from 1.2 to 1.4% by weight of at ieast one catalyst for the polymerization of the cyclic amide, where the ratio by weight of components b) to c) is from 2.0 to 2.9 and the % by weight data are always based on the entirety of components a) to c).

Abstract: A polymer having a hydrophobic polymer chain derived from monomers of farnesene and other optional monomers, such as dienes and vinyl aromatics. The polymer also includes one or more terminal functional groups, such as an amino group, a glycidyl group, a carboxylic acid group, a (meth)acrylate group, a silane group, an isocyanate group, an acetoacetate group, a phenolic group, and a hydroxyl group. Functional groups, such as carboxylic acids, may also be grafted along the hydrophobic polymer chain. The polymer may be incorporated in curable compositions that optionally include one or more polymer resins having similar functional groups. Methods for preparing the curable polymer compositions are also provided. The curable or cured form of the polymer composition may be used in various products, such as a sealant, a coating, a caulk, an electric potting compound, a membrane, a sponge, a foam, an adhesive, or a propellant binder.

Abstract: Provided is a polymer capable of providing a coating film that has good initial adhesiveness to a base material and good adhesiveness thereto after a pressure cooker test, and has excellent abrasion resistance as determined by a falling sand abrasion test. The polymer includes a perhaloolefin unit, a vinyl ester unit that contains neither a hydroxy group nor an aromatic ring; and a hydroxy group-containing monomer unit. The polymer has a hydroxyl value of 110 mgKOH/g or greater.

Abstract: The present invention provides a polyamide-imide, a method for preparing same, and a polyimide film using same. The polyamide-imide film exhibits excellent transparency, heat resistance, mechanical strength and flexibility, and thus may be used in various fields such as substrates for device, cover substrates for displays, optical films, integrated circuit (IC) packages, adhesive films, multi-layer flexible printed circuits (FPCs), tapes, touch panels and protective films for optical discs.

Abstract: A use of a polymerizable ultraviolet absorber is disclosed, which is applied to a polyurethane preparation. The polymerizable ultraviolet absorber is obtained by reacting an UV absorber having a reactive hydrogen group with a polyisocyanate having three —NCO groups. In addition, a composition for forming polyurethane comprising the aforementioned polymerizable ultraviolet absorber is also disclosed.

Abstract: The present disclosure provides alkaline-stable m-terphenyl benzimidazolium hydroxide compounds, in which the C2-position is attached to a phenyl group having various substituents at the ortho positions. Polymers incorporating m-terphenylene repeating groups derived from these alkaline-stable benzimidazolium hydroxide compounds are also presented, along with their inclusion in ionic membranes and in electrochemical devices.

Abstract: The disclosure relates generally to black-to-transmissive electrochromic polymers having superior properties such as absorbance of across the entire visible spectrum and an obvious color change from black to transmissive with an applied voltage. The disclosure also relates to methods for synthesizing or using the same. Further, the disclosure also relates to black-to-transmissive electrochromic polymer thin films comprising the black-to-transmissive electrochromic polymers, as well as electrochromic devices comprising the black-to-transmissive electrochromic polymers or thin films.

Abstract: The present invention relates to compositions containing polymeric carbodiimide, epoxide and polyester-based polymers, their production and use.

Abstract: A method includes combining an alcohol-pharmaceutical conjugate, a polyol, and an aqueous liquid in a vessel. The alcohol-pharmaceutical conjugate includes a pharmaceutical compound having at least one carboxyl group attached to the polyol by an ester bond. The method also includes adding an acid monomer to the vessel and heating and removing water from the vessel to produce the polymeric material. The polymeric material includes a polyester copolymer of the acid monomer and the polyol and the pharmaceutical compound.

Abstract: The present disclosure relates to a copolycarbonate having improved impact strength at low temperature and YI (Yellow Index) simultaneously, and a composition including the same.

Abstract: Provided are a polyol glyceryl ether, and a multi-armed polyethylene glycol and the multi-armed polyethylene glycol active derivative prepared using the same. The multi-armed polyethylene glycol is formed by polymerizing ethylene oxide with the polyol glyceryl ether as an initiator, and has the structure of general formula II, wherein B is a polyol group, n is an integer between 3 and 22, PEG is the same or not the same —(OCH2CH2)m—, and the average value of m is an integer between 3 and 250. The multi-armed polyethylene glycol has a relatively low poly-dispersity and a relatively high determined molecular weight. Also provided is a conjugate of the multi-armed polyethylene glycol active derivative and pharmaceutical molecules, a pharmaceutical composition comprising the conjugate, and a gel formed by the multi-armed polyethylene glycol active derivative. The gel can be used to prepare a sustained-release drug for prolonging the time of the drug action.

Abstract: Disclosed is a process for making a polyetheramine containing polyamide without excessive foaming in successive batches by providing a controlled heat input rate step for those batch runs that incorporate polyetheramine containing polyamide heel from previous runs.

Abstract: A process for preparing polymeric compounds comprising ionic imidazolium groups (polymeric imidazolium compounds for short) comprising reacting —an ?-dicarbonyl compound, —an amino compound having at least two primary amino groups (referred to as oligoamine), —a protic acid, —less than 1 mol of a compound with only one aldehyde group (referred to as monoaldehyde) per mol of oligoamine and —optionally further compounds.

Abstract: Described herein are associative polymers capable of controlling a physical and/or chemical property of non-polar compositions and related compositions, methods and systems. Associative polymers herein described have a non-polar backbone and functional groups presented at ends of the non-polar backbone, with a number of the functional groups presented at the ends of the non-polar backbone formed by associative functional groups capable of undergoing an associative interaction with another associative functional group with an association constant (k) such that the strength of each associative interaction is less than the strength of a covalent bond between atoms and in particular less than the strength of a covalent bond between backbone atoms.

Abstract: Methods according to the present invention decolorize a polymer by mixing a solution of the polymer with a photocatalyst and exposing the mixture to ultraviolet light; by way of non-limiting example, the polymer may be a star polymer and the photocatalyst may be titanium dioxide. Methods according to the present invention also utilize a metal scavenger, in some embodiments a solid-phase metal scavenger, to remove a metal catalyst from a polymer solution; by way of non-limiting example, the metal catalyst may be a tin catalyst. The decolorization methods and the catalyst removal methods of the present invention may be practiced separately, sequentially in any order, or simultaneously.